NeoGenomics Stock Plunge: Exact Sciences Launches Cancerguard
Update: 2025-09-10
Description
NeoGenomics stock plummets as Exact Sciences unveils Cancerguard, a new early cancer detection blood test, intensifying competition in the cancer diagnostics market. Is this a buying opportunity amidst NeoGenomics' volatile year, marked by both a major patent win and a significant year-to-date stock decline? Find out how this new technology could reshape the future of cancer diagnostics and what it means for investors.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
